Listen to EASL Podcasts podcast

EASL Studio Podcast: Does it really matter whether we call it ACLF or acute decompensation?	EASL Podcasts	31:23
EASL Studio Podcast: The Clinical Blind Spot: Are We Neglecting Alcohol?	EASL Podcasts	34:59
EASL Studio Podcast: Hepatitis C, Re-infection or Failure of Treatment in People Engaging in High Risk Practices – Do These Labels Matter in 2025?	EASL Podcasts	35:41
EASL Studio Podcast: What Matters Most? The questions every hepatologist should ask their patients	EASL Podcasts	33:17
EASL DeepDive: Diagnosis, non-invasive screening and risk stratification of MASLD cases	EASL Podcasts	66:33
EASL Studio Podcast: EASL CPGs on Vascular Liver Diseases: What’s New?	EASL Podcasts	32:32
EASL DeepDive: MASLD Cirrhosis: Addressing unmet needs and defining valuable endpoints	EASL Podcasts	70:01
EASL Studio Podcast: Steatotic Liver Disease Unpacked: Targeting Dynamic Risks	EASL Podcasts	35:58
EASL Studio Podcast: Artificial Intelligence: Is This the Beginning of the End of the Medical Profession as We Know It?	EASL Podcasts	36:41
EASL Studio Podcast: Rethinking Hepatitis B: Discussions with Patients – Adapting to Expanding Treatment Guidelines	EASL Podcasts	36:08
EASL Studio Podcast: Interprofessional Session: Implementing the New EASL MASLD Guidelines into Clinical Practice	EASL Podcasts	27:50
EASL/CIRSE Studio Podcast: Interventional radiology in hepatology: Building bridges to optimise care	EASL Podcasts	30:55
EASL Studio Podcast: Beyond the myths: Alcohol harm and policy action	EASL Podcasts	47:13
EASL Studio Podcast: Screening strategies for liver fibrosis	EASL Podcasts	31:26
EASL Studio Podcast: Landmark studies at EASL Congress 2025	EASL Podcasts	36:18
EASL DeepDive: Key for TIPS Success: Identifying Suitable Candidates and Risk Control	EASL Podcasts	92:14
EASL Studio Podcast: Endoscopic Management of Variceal Bleeding: Outdated or Evolving Beyond Tradition?	EASL Podcasts	45:41
EASL DeepDive: Glucagon in MASH: A next step in “metabolic” drugs tackling liver disease?	EASL Podcasts	66:16
EASL DeepDive: Understanding and managing PBC symptoms	EASL Podcasts	75:22
EASL DeepDive: Evolving insights in role and management of Alpha-1 Antitrypsin Deficiency	EASL Podcasts	67:15
EASL DeepDive: What is the future of PBC treatment?	EASL Podcasts	59:19
EASL Studio Podcast: JHEP Live: JHEP at 40: What to Expect Next?	EASL Podcasts	62:22
EASL Studio Podcast: Rare Liver Malignancies: Small Numbers, Big Questions	EASL Podcasts	44:52
EASL Studio Podcast: From Evidence to Action: Reducing Alcohol-Related Harm	EASL Podcasts	32:05
EASL Studio Podcast: Understanding Sex Disparities in MASLD	EASL Podcasts	40:40
EASL Studio Podcast: Lessons from Your PET: Understanding and Evaluating Treatment for Wilson’s Disease	EASL Podcasts	38:48
EASL Studio Podcast: Liver Cancer Care in 2025: Progress, Hope, and What Lies Ahead	EASL Podcasts	44:46
EASL Studio Podcast: YI choice: From Idea to Abstract to Publication: Navigating Your Research journey	EASL Podcasts	31:49
EASL Studio Podcast: JHEP Live – EASL CPGs on Hepatocellular Carcinoma: What’s New and How Will Practice Change?	EASL Podcasts	48:38
EASL Studio Podcast: 2025 Update on Steatotic Liver Disease: Rethinking Standard of Care	EASL Podcasts	34:33
EASL Studio Podcast: The liver as a master regulator of ageing, health, and longevity	EASL Podcasts	35:56
EASL Studio Podcast: TIPS: How far can we go?	EASL Podcasts	36:16
EASL Studio Podcast: Sarcopenia: Converting research findings into clinical practice - Are we doing enough?	EASL Podcasts	30:38
EASL Studio Podcast: Alcohol, cardiometabolic risks factors, and steatotic liver disease – From stigma to breakthrough therapies	EASL Podcasts	35:44
EASL Studio Podcast: What’s hot and not in liver transplantation: EASL CPG 2024 update	EASL Podcasts	44:56
EASL Studio Podcast: Why does WHO engagement with Steatotic Liver Disease matter?	EASL Podcasts	36:16
EASL Studio Podcast: Is it time to abandon the use of ultrasound for HCC surveillance in MASLD?	EASL Podcasts	49:56
EASL Studio Podcast: Are we relearning how to manage renal dysfunction in cirrhosis?	EASL Podcasts	38:30
EASL Studio Podcast: Buongiorno Milano: What not to miss during EASL Congress	EASL Podcasts	24:31
EASL Studio Podcast: Advances in systemic treatments in liver cancer	EASL Podcasts	31:07

EASL Studio Podcast: Does it really matter whether we call it ACLF or acute decompensation?

31:23

EASL Studio Podcast: The Clinical Blind Spot: Are We Neglecting Alcohol?

34:59

EASL Studio Podcast: Hepatitis C, Re-infection or Failure of Treatment in People Engaging in High Risk Practices – Do These Labels Matter in 2025?

EASL Podcasts

35:41

EASL Studio Podcast: What Matters Most? The questions every hepatologist should ask their patients

EASL Podcasts

33:17

EASL DeepDive: Diagnosis, non-invasive screening and risk stratification of MASLD cases

EASL Podcasts